Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
A SominandaA Fogdell-Hahn

Abstract

Neutralizing antibody (NAb) titres may vary over time and thereby some patients can either lose or regain therapeutic effect of interferon beta (IFNbeta). We assessed NAb titres in a large sample of multiple sclerosis (MS) patients to identify the pattern of fluctuation during 1-3 years. Data from IFNbeta-treated MS patients who had been tested for NAbs twice (n = 822) were analysed. NAb titres were compared between the first and the second samples across the critical NAb level of 150 TRU/ml, which we have previously reported to correlate with loss of bioactivity. Of patients with NAb titres high enough to indicate loss of bioactivity (>150 TRU/ml) in the first analysis 15% showed titres low enough to indicate a regained bioactivity. Conversely, 6% of those without detectable NAbs or NAb titres below the critical level of 150 TRU/ml had shifted to titres above this limit, indicating potential loss of bioactivity. Fluctuation did not differ between IFNbeta preparation used, treatment duration or sampling interval. A first NAb test is prognostic for the NAb status during the coming 1-3 years. Choice of IFNbeta preparation had no influence on the chance of reverting to lower levels once NAb titres are high.

References

Jan 1, 1986·Methods in Enzymology·Y Kawade
Jan 7, 1999·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·E PungorS E Grossberg
May 16, 2000·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P KivisäkkH Link
Oct 29, 2000·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J MontplaisirD Petit
Jun 27, 2001·Neurology·UNKNOWN PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.
Oct 25, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·G GiovannoniF Deisenhammer
Oct 22, 2003·Journal of the Neurological Sciences·Francesca BellomiGuido Antonelli
Nov 12, 2003·Neurology·Huub Schellekens
Oct 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·C GneissF Deisenhammer
May 13, 2005·Neurology·P Soelberg SorensenUNKNOWN Danish Multiple Sclerosis Study Group
May 14, 2005·Current Opinion in Neurology·Joep Killestein, Chris H Polman
Jul 13, 2005·Neurology·L KapposUNKNOWN European Interferon Beta-1a IM Dose-Comparison Study Investigators
Jul 13, 2005·Neurology·Gordon S FrancisUNKNOWN PRISMS Study Group
Oct 26, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P S SørensenUNKNOWN EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis
Oct 4, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·A SominandaA Fogdell-Hahn

❮ Previous
Next ❯

Citations

Jan 14, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Sidney E GrossbergJohn P Klein
Sep 30, 2010·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Miranda M C van BeersHuub Schellekens
Dec 18, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P S Sorensen
May 4, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Roger JungedalAnna Fogdell-Hahn

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.